Journal List > Infect Chemother > v.43(3) > 1035087

Cho, Park, Park, Moon, Chong, Kim, Lee, Choi, Woo, Kim, and Kim: Drug-Resistant Extrapulmonary Tuberculosis

Abstract

The prevalence and pattern of drug-resistant extrapulmonary tuberculosis (TB) is not well characterized in Korea. Therefore, we assessed the incidence of drug resistance for extrapulmonary TB in adult patients at a tertiary hospital. We retrospectively reviewed the medical records and results of drug susceptibility test in all culture-confirmed extapulmonary TB patients during an 18-month period. Out of a total of 168 cases in which the drug susceptibility test was performed, resistance to at least one anti-TB drug was found in 15 cases (8.9%), and multidrug resistance, in which TB was resistant to at least isoniazid and rifampin, was found in 3 cases (1.8%)

Figures and Tables

Table 1
Clinical Characteristics of 168 Patients with Drug Sensitive and Resistant Extrapulomonary Tuberculosis
ic-43-258-i001

Data presented as number (%) or numbers positive/number tested (%) unless otherwise indicated. TB, tuberculsosis; AFB, acid-fast bacilli; PCR, polymerase chain reaction.

aPatients may have ≥1 suspected sites of infection.

bIncluded cases with isolation of M. tuberculosis, positive M. tuberculosis polymerase chain reaction, or histologic demonstration of caseating granulmatous inflammation from the bone marrow, at least 2 noncontiguous organs, or miliary lung lesions.

Table 2
Drug Resistance Pattern of Extrapulmonary Tuberculosis
ic-43-258-i002

Data are presented as number (%).

INH, isoniazid; RMP, rifampin; EMB, ethambutol; PZA, pyrazinamide; SM, streptomycin; KM, kanamycin; PTH, prothionamide; OFX, ofloxacin; CNS, central Nervous System.

Table 3
Resistance Proportions of Each Anti-Tuberculosis Drug
ic-43-258-i003

INH, isoniazid; RMP, rifampin; EMB, ethambutol; PZA, pyrazinamide; SM, streptomycin; KM, kanamycin; PTH, prothionamide; OFX, ofloxacin.

References

1. Anti-tuberculous drug resistance surveillance in Korea. Korean National Tuberculosis Association. Accessed 1 February 2011. Available from: http://www.knta.or.kr/.
2. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis. 2009. 49:1350–1357.
crossref
3. Park WI, Kang BS, Park JS, Nam JY, Kim CS, Kim JU, Kim DY, Kim TM, Yoon SJ, Huh AJ, Yeom JS, Chang KH, Song YG, Kim JM. Clinical manifestations and diagnosis of extrapulmonary tuberculosis. Korean J Infect Dis. 2002. 34:47–54.
4. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med. 2007. 167:2255–2259.
crossref
5. Cho OH, Park KH, Kim T, Song EH, Jang EY, Lee EJ, Chong YP, Choi SH, Lee SO, Woo JH, Kim YS, Kim SH. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect. 2009. 59:56–61.
crossref
6. Lin JN, Lai CH, Chen YH, Lee SS, Tsai SS, Huang CK, Chung HC, Liang SH, Lin HH. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009. 13:620–625.
7. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, Cave MD, Bates JH. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004. 38:199–205.
crossref
8. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2006.362. 2006. Geneva: WHO.
9. Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, Cheung WC, Yuen KY. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003. 22:597–602.
crossref
10. Song EJ, Baek DH, Jung JY, Lee SR, Lee MH, Lee SH, Lee JH, Lee KD, Lee BH, Kim SH. Paradoxical response developed during the antituberculous treatment in tuberculous pleurisy. Tuberc Respir Dis. 2008. 64:427–432.
crossref
11. Al-Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med. 1996. 90:211–214.
crossref
12. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.
13. Kim MJ, Kim HR, Hwang SS, Kim YW, Han SK, Shim YS, Yim JJ. Prevalence and its predictors of extrapulmonary involvement in patients with pulmonary tuberculosis. J Korean Med Sci. 2009. 24:237–241.
crossref
14. Kong JH, Lee SS, Kang HY, Park JS. The prevalence of initial drug resistance among pulmonary tuberculosis patients. Tuberc Respir Dis. 2008. 64:95–101.
crossref
15. Yang H, Field SK, Fisher DA, Cowie RL. Tuberculosis in Calgary, Canada, 1995-2002: site of disease and drug susceptibility. Int J Tuberc Lung Dis. 2005. 9:288–293.
TOOLS
Similar articles